Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
CD44 Antibody (VFF-327) - variant 3 - BSA Free

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NB10064994
Description
CD44 Monoclonal specifically detects CD44 in Human samples. It is validated for Flow Cytometry, Immunohistochemistry, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen.Specifications
CD44 | |
Monoclonal | |
1.0 mg/mL | |
Flow Cytometry 10 ug/ml, Immunohistochemistry 1:10-1:500, Immunohistochemistry-Paraffin 10 ug/ml, Immunohistochemistry-Frozen 10 ug/ml | |
CD44 antigen, CD44 molecule (Indian blood group), CD44R, CDw44, cell surface glycoprotein CD44, chondroitin sulfate proteoglycan 8, CSPG8, ECMR-III, Epican, Extracellular matrix receptor III, GP90 lymphocyte homing/adhesion receptor, HCELL, hematopoietic cell E- and L-selectin ligand, Heparan sulfate proteoglycan, Hermes antigen, homing function and Indian blood group system, HUTCH-I, Hyaluronate receptor, IN, LHR, MC56, MDU2CD44 antigen (homing function and Indian blood group system), MDU3CDW44, MIC4MGC10468, Pgp1, PGP-1, PGP-I, Phagocytic glycoprotein 1, Phagocytic glycoprotein I | |
Mouse | |
Protein A or G purified | |
RUO | |
Primary | |
Specifically recognizes an epitope encoded by exon V3 on the variant portion of human CD44. | |
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. | |
IgG1 |
Flow Cytometry, Immunohistochemistry, Immunohistochemistry (Paraffin), Immunohistochemistry (Frozen) | |
VFF-327 | |
Unconjugated | |
P16070 | |
CD44 | |
Made to Human CD44v3 | |
0.1 mg | |
Cancer, Cell Biology, Extracellular Matrix, Hematopoietic Stem Cell Markers, Immunology, Mesenchymal Stem Cell Markers, Signal Transduction, Stem Cell Markers | |
960 | |
Human | |
Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction